Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Multi-transfused Thalassemia Patients
NCT06888232Completed
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of thalidomide in thalassemia. Primary endpoints: Efficacy of treatment at 6 months and Safety of treatment at 6 months. Started Aug 2023; status: completed.
02
Drugs
thalidomide
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT06888232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888232.